Zwierzyńska Ewa, Pietrzak Bogusława
Zakład Farmakodynamiki Uniwersytetu Medycznego w Łodzi.
Postepy Hig Med Dosw (Online). 2013 Sep 12;67:973-81. doi: 10.5604/17322693.1066537.
Retigabine belongs to a new generation of antiepileptic drugs. Its mechanism of action is different from that previously known. Retigabine opens potassium channels of subfamily Kv 7, especially Kv 7.2 and Kv 7.3. The drug enhances GABA-ergic transmission. It is well absorbed from the digestive system and undergoes metabolism via glucuronidation and acetylation. There is no interaction between retigabine and other antiepileptic drugs except lamotrigine. The drug has been registered as treatment of partial onset seizures with or without secondary generalization in adults. The efficacy of retigabine is being tested in other types of seizures and disorders characterized by neuronal hyperexcitability. Neuroprotective activity of retigabine is also being researched.
瑞替加滨属于新一代抗癫痫药物。其作用机制与先前已知的不同。瑞替加滨可打开Kv 7亚家族的钾通道，尤其是Kv 7.2和Kv 7.3。该药物可增强GABA能传递。它从消化系统吸收良好，并通过葡萄糖醛酸化和乙酰化进行代谢。除拉莫三嗪外，瑞替加滨与其他抗癫痫药物之间没有相互作用。该药物已注册用于治疗成人伴有或不伴有继发性全身性发作的部分性发作。瑞替加滨在其他类型的癫痫发作和以神经元过度兴奋为特征的疾病中的疗效正在进行测试。瑞替加滨的神经保护活性也正在研究中。
